Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Venetoclax (VEN) in combination with azacitidine (AZA) (VEN-AZA) is used to treat acute myeloid leukemia (AML) in patients who are not candidates for intensive chemotherapy but research on prognostic factors remains limited.
Methods: Measurable residual disease (MRD) by multiparametric flow cytometry in AML is important but there is limited evidence of the clinical utility of monitoring MRD in patients treated with VEN-AZA. Herein, a total of 75 patients newly diagnosed with AML treated with VEN-AZA were retrospectively analyzed to examine the role and timing of MRD to predict survival. MRD enabled the categorization of patients into two groups: Day 14 MRD, >1% (MRD); and Day 14 MRD, ≤1% (MRD).
Results: Of the 75 patients, 31 (41.3%) had MRD, whereas 30 (40.0%) had not achieved complete remission (CR) after induction. MRD was associated with improved overall survival (OS) (p = .024) and event-free survival (EFS) (p = .044). In addition, MRD (p = .002 for both OS and EFS), CSF3R negative (CSF3R) (p < .001 for both OS and EFS), and transplantation (p = .005 for OS; p = .007 for EFS) were associated with improved survival outcomes. Further subgroup analysis revealed that MRD patients who underwent transplantation showed a trend toward longer OS and EFS (p < .001 for both).
Conclusions: Results in the MRD group were better than in the MRD group, and the prognosis for patients with AML was better when there was CSF3R and transplantation. Additionally, for patients with AML with MRD, consolidation with transplantation may increase survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.70053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concentration and integrity index of circulating cell-free DNA as a biomarker in pediatric patients with B-ALL.
Cell Mol Biol (Noisy-le-grand)
September 2025
Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Jalisco, México.
The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases.
View Article and Find Full Text PDFMinimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.
Blood Neoplasia
November 2025
Section of Hematology/Oncology, The University of Chicago, Chicago, IL.
Modern multiple myeloma treatment enables deep and sustained responses, necessitating assessment of minimal residual disease (MRD) in the bone marrow to refine response categorization. Recently, mass spectrometry (MS)-based methods have emerged as highly sensitive tools for measuring MRD in the peripheral blood. However, the role specific MS techniques play in response categorization has yet to be established.
View Article and Find Full Text PDFDevelopment and Validation of a Semiautomated Tool for Measuring Periorbital Distances.
Ophthalmol Sci
July 2025
Illinois Eye and Ear Infirmary, Department of Ophthalmology, University of Illinois at Chicago, Chicago, Illinois.
Purpose: To validate a custom FIJI (ImageJ) program for more reproducible, faster curvilinear periorbital measurements, as compared with 2 custom artificial intelligence-based tools.
Design: Combined technical validation and method comparison study.
Subjects: Front-facing photographs of 45 cleft palate syndromic patients.
Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.
Br J Haematol
September 2025
First Department of Medicine-Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Circulating tumour DNA (ctDNA) is a promising biomarker for diffuse large B-cell lymphoma (DLBCL) risk stratification and treatment response assessment, but real-world studies were limited. Using a targeted sequencing approach (521-gene panel), we showed that (1) baseline ctDNA level correlated with tumour burden and was an independent predictor of treatment outcome, (2) achievement of minimal residual disease (MRD) negativity was associated with a better treatment outcome and (3) interim MRD-positivity combined with positron emission tomography/computed tomography scan-positivity identified a high-risk subgroup of DLBCL patients. Baseline ctDNA level and treatment related achievement of MRD negativity are valuable prognostic tools in DLBCL to improve risk stratification in routine clinical practice.
View Article and Find Full Text PDFIt's "Blin" a Long Time Coming: The Rise of Blinatumomab in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk
August 2025
Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI. Electronic address:
Blinatumomab is a bispecific T-cell engager that has recently transformed front-line treatment for many patients with Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). It was originally studied in relapsed/refractory disease, then moved to targeting measurable residual disease (MRD), and has since been shown to improve outcomes for almost every age group when added to consolidation chemotherapy. The evidence supporting blinatumomab is most robust in adult and standard-risk pediatric age groups, but its benefit in adolescents and young adults and high-risk pediatric patients is not yet understood.
View Article and Find Full Text PDF